NCT07171905View on ClinicalTrials.gov

CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

May 31, 2027

Conditions
VHL - Von Hippel-Lindau Syndrome
Interventions
DRUG

investigating the role of CAIX as target in VHL disease and in VHL-/- tumors.

Participants VHL disease and in VHL-/- tumors, will receive a single dose of the diagnostic radiopharmaceutical \[89Zr\]Zr-DFO-Girentuximab and subsequently undergo imaging with a hybrid PET/CT scanner.

All Listed Sponsors
lead

IRCCS Ospedale San Raffaele

OTHER